Great Novel Therapeutics Biotech & Medicals (TPEX:7427)

Taiwan · Delayed Price · Currency is TWD

48.10

-2.00 (-3.99%)

Jul 14, 2026, 1:24 PM CST

48.46% (1Y)

Market Cap	2.05B +26.7%
Revenue (ttm)	1.21M -28.5%
Net Income	-97.47M
EPS	-2.26
Shares Out	42.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,884
Open	50.10
Previous Close	50.10
Day's Range	46.85 - 50.10
52-Week Range	29.25 - 57.00
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About TPEX:7427

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan. The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity. It is also developing Kepida to treat HR+/her-2 advanced breast cancer a... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Employees 22

Stock Exchange Taipei Exchange

Ticker Symbol 7427

Full Company Profile

Financial Performance

In 2025, TPEX:7427's revenue was 1.21 million, a decrease of -28.49% compared to the previous year's 1.69 million. Losses were -97.47 million, -7.10% less than in 2024.

Financial Statements